BACKGROUND: Differences in adverse events by gender and race/ethnicity have not been described extensively in randomized clinical trials of HIV antiretroviral therapy (ART). METHODS:Antiretroviral-naive HIV-infected participants enrolled in a long-term randomized clinical trial of 3 different initialART strategies -- protease inhibitor (PI), nonnucleoside reverse transcriptase inhibitor (NNRTI), or PI plus NNRTI-based combinations -- with a median follow-up of 5 years, were compared by gender and race for 14 categories of grade 4 adverse events, discontinuation of initial antiretroviral regimen, and all-cause mortality. Multivariate analysis was used to identify predictors of events and death. RESULTS: Among 1301 participants with complete data, there were 701 blacks, 225 Latinos, and 263 women. Several baseline characteristics differed by gender and race, including age, HIV transmission risk, hepatitis B or C coinfection, viral load, diagnosis of AIDS, body mass index, and baseline hypertension. Grade 4 events occurred in 409 participants (rate: 8.9/100 person-years). There were 176 deaths (rate: 3.0/100 person-years) and 523 discontinuations of regimen for any toxicity (rate: 13/100 person-years). In the fully adjusted regressions, blacks had greater risk for cardiovascular (hazard ratio [HR] = 2.64, 95% confidence interval [CI]: 1.04 to 6.67) and renal (HR = 3.83, 95% CI: 1.28 to 11.5) events. Black men had more psychiatric events (HR = 2.45, 95% CI: 1.13 to 5.30). Women had a higher risk for anemia (HR = 2.34, 95% CI: 1.09 to 4.99). CONCLUSION: Among HIV-infected participants initiating ART, there were significant risk-adjusted differences for specific adverse events by gender and race but not in the overall adverse event rates, all-cause mortality, or rates of toxicity-related treatment discontinuations.
RCT Entities:
BACKGROUND: Differences in adverse events by gender and race/ethnicity have not been described extensively in randomized clinical trials of HIV antiretroviral therapy (ART). METHODS: Antiretroviral-naive HIV-infectedparticipants enrolled in a long-term randomized clinical trial of 3 different initial ART strategies -- protease inhibitor (PI), nonnucleoside reverse transcriptase inhibitor (NNRTI), or PI plus NNRTI-based combinations -- with a median follow-up of 5 years, were compared by gender and race for 14 categories of grade 4 adverse events, discontinuation of initial antiretroviral regimen, and all-cause mortality. Multivariate analysis was used to identify predictors of events and death. RESULTS: Among 1301 participants with complete data, there were 701 blacks, 225 Latinos, and 263 women. Several baseline characteristics differed by gender and race, including age, HIV transmission risk, hepatitis B or C coinfection, viral load, diagnosis of AIDS, body mass index, and baseline hypertension. Grade 4 events occurred in 409 participants (rate: 8.9/100 person-years). There were 176 deaths (rate: 3.0/100 person-years) and 523 discontinuations of regimen for any toxicity (rate: 13/100 person-years). In the fully adjusted regressions, blacks had greater risk for cardiovascular (hazard ratio [HR] = 2.64, 95% confidence interval [CI]: 1.04 to 6.67) and renal (HR = 3.83, 95% CI: 1.28 to 11.5) events. Black men had more psychiatric events (HR = 2.45, 95% CI: 1.13 to 5.30). Women had a higher risk for anemia (HR = 2.34, 95% CI: 1.09 to 4.99). CONCLUSION: Among HIV-infectedparticipants initiating ART, there were significant risk-adjusted differences for specific adverse events by gender and race but not in the overall adverse event rates, all-cause mortality, or rates of toxicity-related treatment discontinuations.
Authors: Thomas P Giordano; Glenn Bartsch; Yafeng Zhang; Ellen Tedaldi; Judith Absalon; Sharon Mannheimer; Avis Thomas; Rodger D MacArthur Journal: AIDS Patient Care STDS Date: 2010-05 Impact factor: 5.078
Authors: Michael J Silverberg; Lisa P Jacobson; Audrey L French; Mallory D Witt; Stephen J Gange Journal: J Pain Symptom Manage Date: 2009-03-28 Impact factor: 3.612
Authors: Debika Bhattacharya; T Umbleja; F Carrat; R T Chung; M G Peters; F Torriani; J Andersen; J S Currier Journal: J Acquir Immune Defic Syndr Date: 2010-10 Impact factor: 3.731
Authors: Carina Cesar; Bryan E Shepherd; Alejandro J Krolewiecki; Valeria I Fink; Mauro Schechter; Suely H Tuboi; Marcelo Wolff; Jean W Pape; Paul Leger; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Omar Sued; Catherine C McGowan; Daniel R Masys; Pedro E Cahn Journal: PLoS One Date: 2010-06-01 Impact factor: 3.240
Authors: Arif Alibhai; Walter Kipp; L Duncan Saunders; Ambikaipakan Senthilselvan; Amy Kaler; Stan Houston; Joseph Konde-Lule; Joa Okech-Ojony; Tom Rubaale Journal: Int J Womens Health Date: 2010-08-09
Authors: Edward R Hammond; Rosa M Crum; Glenn J Treisman; Shruti H Mehta; Christina M Marra; David B Clifford; Susan Morgello; David M Simpson; Benjamin B Gelman; Ronald J Ellis; Igor Grant; Scott L Letendre; Justin C McArthur Journal: Am J Epidemiol Date: 2014-06-24 Impact factor: 4.897